Floatz logo

Bexarotene

Lymphoma, Large-Cell, Anaplastic

Case Comprehensive Cancer CenterSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Lymphoma, Large-Cell, Anaplastic cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Seagen Inc.
Phase 4BBB
Crizotinib
Pfizer
Phase 4BBB
Inno-206
City of Hope Medical Center
Phase 4BBB
Brentuximab Vedotin
Seagen Inc.
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Bexarotene is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
primary cutaneous anaplastic large cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
mycosis fungoidesDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →